New hope for pancreatic cancer patients: experimental drug combo enters testing
NCT ID NCT06951997
Summary
This study is testing whether adding two new immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy works better for people with metastatic pancreatic cancer. The trial will enroll 33 patients who haven't had any prior cancer treatment to see if this combination can shrink tumors and extend survival. Researchers will carefully monitor how well the treatment works and what side effects patients experience.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.